In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis. © Springer-Verlag 2005.
CITATION STYLE
Ringe, J. D., Dorst, A., Faber, H., Kipshoven, C., Rovati, L. C., & Setnikar, I. (2005). Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: A pilot study. Rheumatology International, 25(4), 296–300. https://doi.org/10.1007/s00296-004-0570-x
Mendeley helps you to discover research relevant for your work.